18 March 2020 - The U.S. Food and Drug Administration today issued a guidance for industry, investigators and institutional review boards conducting clinical trials during the coronavirus (COVID-19) pandemic.

The FDA recognises that the COVID-19 pandemic may impact the conduct of clinical trials of medical products, including drugs, devices and biological products. 

Challenges may arise, for example, from quarantines, site closures, travel limitations, interruptions to the supply chain for the investigational product, or other considerations if site personnel or trial subjects become infected with SARS-CoV-2, the virus that causes COVID-19.

Read FDA press release